www.nuzyra.com
Open in
urlscan Pro
162.209.115.31
Public Scan
Submitted URL: http://click.hg-email.com/?qs=f932bfe19ff76597f6ed0cc52dbb798fdac1838dd10319c3cc5a1ff3b985ebe0de8a13a3f11450ea544bc8efa7ac...
Effective URL: https://www.nuzyra.com/hcp/pharmacy-finder
Submission: On January 24 via manual from US — Scanned from DE
Effective URL: https://www.nuzyra.com/hcp/pharmacy-finder
Submission: On January 24 via manual from US — Scanned from DE
Form analysis 3 forms found in the DOM
<form>
<div class="form-row ">
<div class="col-lg-5 col-sm-12">
<div class="form-group mapFormRow">
<label for="formGroupExampleInput2" class="zipLabel ">City & State or ZIP Code</label>
<input type="text" class="form-control inputAddress" id="formGroupExampleInput2" placeholder="City & State or ZIP Code">
</div>
</div>
<div class="form-group radiusInput no-gutters has-error">
<label class="col-12 control-label" for="radiusInput"> Radius<span class="error">*</span>
</label>
<div id="spec-input" class="col-12 radiusFormInputBox">
<input id="radiusInput" class="form-control radiusForm selectized" type="text" placeholder="20 mi" name="radiusInput" autocomplete="nope" data-element="default" data-category="Sign Up" data-action="Form" data-label="Your Specialty"
tabindex="-1" value="" style="display: none;">
<div class="selectize-control form-control radiusForm single">
<div class="selectize-input items not-full has-options"><input type="text" autocomplete="off" tabindex="" placeholder="20 mi" style="width: 40.8906px;"></div>
<div class="selectize-dropdown single form-control radiusForm" style="display: none;">
<div class="selectize-dropdown-content"></div>
</div>
</div>
<img src="img/selectArrow.png" alt="" class="selectArrowDropDown">
</div>
</div>
<button class="inactive" id="downloadPdfButton">
<p id="downloadPdfButtonText">DOWNLOAD PDF</p>
<img src="img/downArrow.png" alt="" class="downArrow">
</button>
<button data-category="Pharmacy Finder" data-action="Click" data-label="Successful Search" data-event="Pharmacy Finder" class="btn dailyBtn" id="pharmaFinderBtn">
<p class="microBtnTextOne" id="pharmaFinderBtnText">Search</p>
<img src="img/aboutImg/arrowThree.png" alt="" class="buttonArrowOne pharmfinderArrow">
</button>
</div>
</form>POST /hcp/api/download-pharmacy-finder-pdf.php
<form id="pdf-form" action="/hcp/api/download-pharmacy-finder-pdf.php" method="post">
<input name="arr" type="text" id="arr">
</form>POST /hcp/api/download-pharmacy-list-pdf.php
<form id="pdf-list-form" action="/hcp/api/download-pharmacy-list-pdf.php" method="post">
<input name="pdf-list-arr" type="text" id="pdf-list-arr">
</form>Text Content
* For US Healthcare Professionals only * PRESCRIBING INFORMATION * REQUEST A REP / SAMPLE NUZYRA is indicated for treatment of Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in adults caused by select susceptible microorganisms. See complete Indications and Usage below. -------------------------------------------------------------------------------- * ABOUT NUZYRA * ANTIMICROBIAL ACTIVITY * DOSING CABP Dosing ABSSSI Dosing * EFFICACY CABP Efficacy ABSSSI Efficacy * CLINICAL SAFETY CABP Safety ABSSSI Safety * ACCESS SUPPORT Prescribe NUZYRA Pharmacy Finder Resources * STAY UP TO DATE NUZYRA is indicated for treatment of Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in adults caused by select susceptible microorganisms. See complete Indications and Usage below. -------------------------------------------------------------------------------- * PRESCRIBING INFORMATION * REQUEST A REP/SAMPLE -------------------------------------------------------------------------------- For US Healthcare Professionals only * ABOUT NUZYRA -------------------------------------------------------------------------------- * ANTIMICROBIAL ACTIVITY -------------------------------------------------------------------------------- * DOSING CABP Dosing ABSSSI Dosing -------------------------------------------------------------------------------- * EFFICACY CABP Efficacy ABSSSI Efficacy -------------------------------------------------------------------------------- * CLINICAL SAFETY CABP Safety ABSSSI Safety -------------------------------------------------------------------------------- * ACCESS SUPPORT NUZYRA Central ™ Pharmacy Finder Resources -------------------------------------------------------------------------------- * STAY UP TO DATE -------------------------------------------------------------------------------- * REQUEST A REP/SAMPLE * NUZYRA PHARMACY NETWORK FINDER Use the finder below to locate pharmacies that carry NUZYRA®(omadacycline) tablets. When preparing to provide a patient with a NUZYRA prescription for tablets, please select a pharmacy from the search results below, or from one of the pharmacies listed here. You can e-prescribe, phone in, or fax their prescriptions directly to any pharmacy in the NUZYRA Pharmacy Network. City & State or ZIP Code Radius* DOWNLOAD PDF Search Karte * Gelände Satellit * Beschriftungen Kurzbefehle KartendatenKartendaten © 2022 Google, INEGI Nutzungsbedingungen Fehler bei Google Maps melden Kartendaten © 2022 Google, INEGI * This information is current as of 01/24/2022. NUZYRA is available at pharmacies in the NUZYRA Pharmacy Network. Paratek does not recommend or prefer the use of one pharmacy over another. Inventory may vary. Check with your local pharmacy for availability and additional guidance. PHARMACIES NEAR YOU THERE DON'T SEEM TO BE ANY PHARMACIES IN YOUR SELECTED RADIUS. PLEASE SEE THE LIST OF MAIL ORDER PHARMACIES BELOW, OR CALL NUZYRA CENTRAL ™ AT 1-877-4-NUZYRA (1-877-468-9972). NUZYRA PHARMACY NETWORK All pharmacies are able to provide same day or next day delivery of NUZYRA. Click the button to download the list below. DOWNLOAD PDF CVS Phone 866-833-3752 ext 1036927 Fax 800-323-2445 www.cvsspecialty.com KROGER 6439 Hazeltine National Drive, Suite 140 Orlando, Florida 32822 Phone 855-274-1694 Fax 855-819-6922 www.krogerspecialtypharmacy.com OPTION CARE Phone 800-960-6901 Fax 888-804-7480 www.optioncare.com PANTHERX 24 Summit Park Dr. Pittsburgh, PA 15275 Phone 855-726-8479 Fax 855-246-3986 www.pantherspecialty.com WALGREENS Walgreens Pharmacy at Piedmont Hospital 35 Collier Rd NW Suite 100 Atlanta, Georgia 30309 Phone 404-350-9772 Fax 404-355-8966 Community, a Walgreens Pharmacy 28311 Marguerite Parkway, B-1 Mission Viejo, California 92692 Phone 949-538-3038 Fax 949-538-3039 Walgreens Pharmacy at Baptist Beaumont 3080 College Street Beaumont, Texas 77701 Phone 409-813-1206 Fax 409-813-1261 Community, a Walgreens Pharmacy 115A N Euclid Ave Saint Louis, Missouri 63108 Phone 314-454-6676 Fax 314-367-1881 Community, a Walgreens Pharmacy 912 W Belmont Ave Chicago, Illinois 60657 Phone 773-665-8990 Fax 773-665-9766 www.walgreens.com/pharmacy/specialtypharmacy.jsp Sign up to learn more about NUZYRA INDICATIONS and IMPORTANT SAFETY INFORMATION INDICATIONS NUZYRA® (omadacycline) is a tetracycline-class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms: Community-Acquired Bacterial Pneumonia (CABP) caused by the following: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by the following: Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Staphylococcus lugdunensis, Streptococcus pyogenes, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Enterococcus faecalis, Enterobacter cloacae, and Klebsiella pneumoniae. USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS NUZYRA is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline-class antibacterial drugs, or to any of the excipients. WARNINGS AND PRECAUTIONS Mortality imbalance was observed in the CABP clinical trial with eight deaths (2%) occurring in patients treated with NUZYRA compared to four deaths (1%) in patients treated with moxifloxacin. The cause of the mortality imbalance has not been established. All deaths, in both treatment arms, occurred in patients > 65 years of age; most patients had multiple comorbidities. The causes of death varied and included worsening and/or complications of infection and underlying conditions. Closely monitor clinical response to therapy in CABP patients, particularly in those at higher risk for mortality. The use of NUZYRA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia. The use of NUZYRA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth. Hypersensitivity reactions have been reported with NUZYRA. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with other tetracycline-class antibacterial drugs. NUZYRA is structurally similar to other tetracycline-class antibacterial drugs and is contraindicated in patients with known hypersensitivity to tetracycline-class antibacterial drugs. Discontinue NUZYRA if an allergic reaction occurs. Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs. NUZYRA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions, including photosensitivity, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests), have been reported for other tetracycline-class antibacterial drugs, and may occur with NUZYRA. Discontinue NUZYRA if any of these adverse reactions are suspected. Prescribing NUZYRA in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. ADVERSE REACTIONS The most common adverse reactions (incidence ≥2%) are nausea, vomiting, infusion site reactions, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyl transferase increased, hypertension, headache, diarrhea, insomnia, and constipation. DRUG INTERACTIONS Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage while taking NUZYRA. Absorption of tetracyclines, including NUZYRA is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations. USE IN SPECIFIC POPULATIONS Lactation: Breastfeeding is not recommended during treatment with NUZYRA. To report SUSPECTED ADVERSE REACTIONS, contact Paratek Pharmaceuticals, Inc. at 1-833-727-2835 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Please see Full Prescribing Information for NUZYRA. EXPAND COLLAPSE INDICATIONS and IMPORTANT SAFETY INFORMATION INDICATIONS NUZYRA® (omadacycline) is a tetracycline-class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms: Community-Acquired Bacterial Pneumonia (CABP) caused by the following: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by the following: Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Staphylococcus lugdunensis, Streptococcus pyogenes, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Enterococcus faecalis, Enterobacter cloacae, and Klebsiella pneumoniae. USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS NUZYRA is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline-class antibacterial drugs, or to any of the excipients. WARNINGS AND PRECAUTIONS Mortality imbalance was observed in the CABP clinical trial with eight deaths (2%) occurring in patients treated with NUZYRA compared to four deaths (1%) in patients treated with moxifloxacin. The cause of the mortality imbalance has not been established. All deaths, in both treatment arms, occurred in patients > 65 years of age; most patients had multiple comorbidities. The causes of death varied and included worsening and/or complications of infection and underlying conditions. Closely monitor clinical response to therapy in CABP patients, particularly in those at higher risk for mortality. The use of NUZYRA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia. The use of NUZYRA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth. Hypersensitivity reactions have been reported with NUZYRA. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with other tetracycline-class antibacterial drugs. NUZYRA is structurally similar to other tetracycline-class antibacterial drugs and is contraindicated in patients with known hypersensitivity to tetracycline-class antibacterial drugs. Discontinue NUZYRA if an allergic reaction occurs. Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs. NUZYRA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions, including photosensitivity, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests), have been reported for other tetracycline-class antibacterial drugs, and may occur with NUZYRA. Discontinue NUZYRA if any of these adverse reactions are suspected. Prescribing NUZYRA in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. ADVERSE REACTIONS The most common adverse reactions (incidence ≥2%) are nausea, vomiting, infusion site reactions, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyl transferase increased, hypertension, headache, diarrhea, insomnia, and constipation. DRUG INTERACTIONS Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage while taking NUZYRA. Absorption of tetracyclines, including NUZYRA is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations. USE IN SPECIFIC POPULATIONS Lactation: Breastfeeding is not recommended during treatment with NUZYRA. To report SUSPECTED ADVERSE REACTIONS, contact Paratek Pharmaceuticals, Inc. at 1-833-727-2835 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Please see Full Prescribing Information for NUZYRA. This site is intended for healthcare professionals inside of the US. © 2021 Paratek Pharmaceuticals, Inc. All rights reserved. PARATEK® and the hexagon logo are registered trademarks of Paratek Pharmaceuticals, Inc. NUZYRA® and its design logo are registered trademarks of Paratek Pharmaceuticals, Inc. For medical inquiries or to report an adverse event, or product quality complaint, please contact Paratek Pharmaceuticals, Inc. at 1-833-PARATEK (1-833-727-2835) or www.paratekpharma.com/medical-affairs/medical-information-request. Use of this website is subject to our Terms of Use. * Privacy Policy * Terms of Use * Contact * Site Map * Privacy Policy * Terms of Use * Contact * Site Map US-NUA-0555 10/21 YOU ARE NOW LEAVING NUZYRA.COM. PARATEK IS NOT RESPONSIBLE FOR THE CONTENT OF ANY THIRD PARTY WEBSITES. Cancel OK x YOU ARE NOW LEAVING NUZYRA.COM. PARATEK IS NOT RESPONSIBLE FOR THE CONTENT OF ANY THIRD PARTY WEBSITES. Cancel OK x Kommunicate Live chat ×